Stockreport

Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket [Seeking Alpha]

Sage Therapeutics, Inc.  (SAGE) 
Last sage therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarketSage Therapeutics (NASDAQ:SAGE) is up52% premarket on light volume in response t [Read more]